Where the guideline stands	Not addressed by the guideline
Availability	Prescription
How long before you judge it	8–12 weeks
Pregnancy	Contraindicated in pregnancy because of the retinoid.
Sources behind this page	7, every one linked at the bottom

Cabtreo at a glance. Recommendation strength and evidence certainty are separate axes under GRADE.

What it is

Cabtreo is a fixed-dose gel combining clindamycin phosphate 1.2%, adapalene 0.15% and benzoyl peroxide 3.1%. The FDA approved it on 20 October 2023 for the topical treatment of acne vulgaris in adult and paediatric patients 12 years of age and older, the first fixed-dose triple-combination acne product. The logic is that each component attacks acne differently: clindamycin is a lincosamide antibacterial, adapalene is a retinoid that binds retinoic acid nuclear receptors and normalises how skin cells differentiate and shed, and benzoyl peroxide is an oxidising agent that is bactericidal and keratolytic. Benzoyl peroxide also does stewardship work, suppressing the emergence of clindamycin-resistant bacteria, which is why antibiotic-plus-benzoyl-peroxide pairings exist in the first place.

What the evidence actually shows

The interesting study is the phase 2, because it is the only one that asks whether three drugs beat two. Stein Gold and colleagues (Am J Clin Dermatol 2022;23:93-104) randomized 741 people aged 9 and over with moderate-to-severe acne to the triple gel, to each of the three possible two-drug versions of it, or to vehicle, for 12 weeks. Treatment success (clear or almost clear plus at least a two-grade improvement) was 52.5% on the triple, 27.8% to 30.5% across the three dyads, and 8.1% on vehicle. The triple beat every dyad on treatment success (P ≤ 0.001) and on lesion counts (P < 0.05). That is the strongest single piece of evidence for the product.

The two phase 3 trials were vehicle-controlled only, with no active comparator. They randomized 183 and 180 subjects 2:1. Treatment success at week 12 was 49.6% versus 24.9% in one and 50.5% versus 20.5% in the other. Inflammatory lesions fell 75.7% versus 59.6% and 80.1% versus 56.2%; non-inflammatory lesions 72.7% versus 47.6% and 73.3% versus 49.0%. A pooled analysis (Kircik et al., Dermatol Ther 2024;14:1211-1227) reports 50.0% versus 22.6% success and inflammatory lesions down 77.9% versus 57.9%.

Where does the guideline sit? Nowhere, and that matters. The 2024 AAD guideline’s fixed-dose combination recommendations (1.8 antibiotic plus benzoyl peroxide, 1.9 retinoid plus antibiotic, 1.10 retinoid plus benzoyl peroxide, all strong on moderate-certainty evidence) are about two-drug products. Cabtreo was approved after the guideline’s evidence review closed, so it carries no graded recommendation of any kind. That ungraded status is a timing artefact, not a judgement against it. Each of its three components falls under a recommendation the guideline does make: benzoyl peroxide (1.2) is graded as an agent, while adapalene and clindamycin are covered by the class recommendations for topical retinoids (1.3) and topical antibiotics (1.4) rather than being graded by name, and the guideline’s good practice statement on multimodal topical therapy (1.1) endorses the underlying principle of combining mechanisms.

How it is actually used

A thin layer once daily to the affected areas after washing and drying the face; wash your hands afterwards. Judge it at 12 weeks, the length of the trials. One logistical quirk: pharmacies keep it refrigerated at 2–8°C until it is dispensed, after which it is stored at room temperature and expires 10 weeks from dispensing, so it is not a tube to stockpile. Irritation is most likely in the first four weeks and usually settles. Do not use waxing as a depilatory method on treated skin. Using it alongside other topical acne treatments has not been evaluated, so layering a second retinoid or benzoyl peroxide product on top is guesswork. The label carries a photosensitivity warning: minimise sun exposure and use sunscreen.

Safety and who should avoid it

Almost all the reported adverse reactions are local. Application site pain was reported by 13.6% on Cabtreo versus 0.8% on vehicle, erythema 4.5%, dryness 4.1%, irritation 2.1%, exfoliation 1.7% and dermatitis 1.2%. Clindamycin carries the class warning for severe colitis, which can be fatal; stop the gel if diarrhoea develops. It is contraindicated in people with known hypersensitivity to its components or to lincomycin, and in anyone with a history of regional enteritis, ulcerative colitis or antibiotic-associated colitis. On pregnancy the label is honest rather than alarming: human data are insufficient to evaluate risk, and no animal reproduction studies have been done with the combination.

Commonly repeated: Cabtreo is contraindicated in pregnancy because it contains a retinoid. What the evidence actually shows: the FDA label lists no pregnancy contraindication. Its contraindications are hypersensitivity to the components or to lincomycin, and a history of regional enteritis, ulcerative colitis or antibiotic-associated colitis. What the label says about pregnancy is that available data are insufficient to evaluate a drug-associated risk and that no animal reproduction studies have been conducted with the combination. That is an unknown, not a prohibition, and still a conversation to have with a clinician.

Sources

Keep reading

See where this sits against every other acne treatment on the acne treatment evidence map, or check how it combines with another ingredient in the ingredient combination checker. For the guideline’s own wording on this, see the 2024 AAD guideline, recommendation by recommendation.

Not medical advice

This page reports what the published evidence says about a treatment. It is not a treatment plan and it cannot account for your skin, your other medications or your medical history. Nothing here has been reviewed by a clinician; see our editorial policy for what that means. Talk to a clinician before starting or stopping any prescription treatment.

Research, not medical advice. Every clinical claim above links to the guideline, systematic review, trial or drug label it came from, so you can check it yourself rather than take my word for it. It was researched and drafted with AI assistance by a non-clinician, and no dermatologist has reviewed it: this site does the reading, it doesn’t practise medicine. It can’t account for your circumstances either, so talk to a dermatologist or doctor about your own skin, especially before starting or stopping a prescription treatment.

Cabtreo: The First Triple-Combination Acne Gel